Clinics and pathology
Epidemiology 12p abnormalities are common in a broad spectrum of haematological malignancies (acute lymphoblastic (ALL) or acute myeloid (ANLL) leukaemias, myelodysplastic (MDS) or chronic myeloproliferative syndromes, non-Hodgkin's lymphomas; observed in about 5% of acute non lymphocytic leukaemias and myelodysplastic syndromes; characteristic of secondary leukaemia after prior mutagenic exposure (10%) and associated with a poor prognosis (karyotypes mostly complex)).
Cytogenetics

Cytogenetics, morphological
-Sole anomaly in 20%; numerical and structural rearrangements of chromosomes 5 and 7 frequently associated (found in 50% in de novo cases). -del(12p): due to the very heterogeneous breakpoints in 12p (assigned to all chromosome bands), no cytogenetic subgroups are defined; deletion in 12p is generally associated with a poor prognosis; however, different clinical courses are defined concerning the magnitude of 12p; a group with small deletions has a better prognosis than patients with 12p abnormalities in general and a lower tendency to additional chromosomal rearrangements; submicroscopic deletions of 12p are much more common in lymphoid than in myeloid malignancies; a minimal interstitial deletion region is described, involving ETV6 and CDKN1B genes; homozygous deletion of CDKN1B is rare (the other wild allele never found mutated); none of the malignancies with disease specific changes displayed submicroscopic 12p deletions. -dup(12)(p11.2p13) described in one MDS case after benzole agent exposure. -Additions are frequent, considered as imbalanced translocations. -Translocations: translocations or dicentrics involving 12p are mostly associated with loss of 12p material; a lot of partner bands are described; chromosome 12 breakpoint is most often localized in 12p13, involving ETV6 gene, with fusion of 5' end of ETV6 with 3' end of the partner, and sometimes accompanied with a concomitant deletion of the other ETV6 allele: -t(3;12)(q23;p12.3): described as reciprocal and recurrent, involving ETV6 (heterogeneous breakpoints described) and EVI1, and associated with a poor prognosis. -t(4;12)(q11q13;p12;p13): associated with specific clinical features: CD7-positive ANLL, three-lineage dysplasia, blood and bone marrow basophilia. -t(5;12)(q33;p13): recurrent, described in chronic myelomonocytic leukemia: fusion between HLH domain of ETV6 and transmembrane and cytoplasmic kinase domains of PDGFRb; a variant t(10;12)(q24;p13) is described in MDS in progression with eosinopilia and monocytosis. 
Probes
From telomere to centromere: Corresponding to D12S1455: PAC9015; To CCND2: C139C5, C140H4, C146H1, C213C1; To PRB: CPRB; To ETV6: yacs 958B8, 964C10, cosmids: C5OF4, C163E7, C179AB(5'), C148B6(3'); To CDKN1B: 123C12, 142C5; To KRAS2: 153F12.
